🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Metastatic Castration-resistant Prostate Cancer

Combination Study of Antibiotics With Enzalutamide (PROMIZE) NCT06126731Phase 1, Phase 22 sites📍 Bellinzona📍 Sutton Institute of Cancer Research, United Kingdom · Tests: Enzalutamide 40mg, Amoxicillin 500mg, Metronidazole 400mg, Vancomycin 125mg, Ciprofloxacin 500g Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC NCT06100705Phase 21 site📍 New Haven Yale University · Tests: Testosterone Cypionate, Sipuleucel-T First-Time-in-Human Study of GSK5471713 in Adults With mCRPC NCT07332455Phase 1, Phase 216 sites📍 La Jolla📍 Grand Rapids📍 Philadelphia GlaxoSmithKline · Tests: GSK5471713 A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma NCT03460977Phase 185 sites📍 Tucson📍 Tucson📍 Tucson Pfizer · Tests: Mevrometostat (PF-06821497), Enzalutamide, Itraconazole PROCARE - PROstate Cancer Real World Evidence Registry NCT06835218n/a53 sites📍 Freiburg im Breisgau📍 Heidelberg📍 Mannheim UroTrials Company (GmbH) A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer NCT06067841Phase 115 sites📍 Palo Alto📍 Sarasota📍 Boston Bristol-Myers Squibb · Tests: BMS-986460 Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients NCT06615752Phase 1, Phase 21 site📍 Los Angeles Charles Drew University of Medicine and Science · Tests: green tea and quercetin + docetaxel, Placebo + docetaxel Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection NCT05413850Phase 1, Phase 221 sites📍 Miami📍 Miami📍 Atlanta Blue Earth Therapeutics Ltd · Tests: Lutetium (177Lu) rhPSMA-10.1 Injection, 18F-rhPSMA-7.3 injection (in phase 1 only) The COSMYC Trial (COmbined Suppression of MYC) NCT06922318Phase 21 site📍 Baltimore Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Tests: ZEN-3694, Testosterone cypionate, Enzalutamide, Luteinizing hormone-releasing hormone (LHRH) analogue Predictive Factors for Response to Lutetium-177 PSMA Radioligand Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer NCT07863986n/a1 site📍 Kaunas Lithuanian University of Health Sciences · Tests: [177Lu]Lu-PSMA-617 (Pluvicto, Novartis), 68Ga-PSMA-11 PET/CT, Post-therapy 177Lu-PSMA SPECT/CT dosimetry, Circulating t… 177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer NCT07145177Phase 11 site📍 San Francisco University of California, San Francisco · Tests: 177Lu-PSMA-617, Ablation, Trans-arterial chemoembolization (TACE), Positron Emission Tomography (PET)/Computerized tomo… A Study in Patients With Metastatic Castration-Resistant Prostate Cancer NCT07719361Phase 110 sites📍 Los Angeles📍 Boston📍 Boston Flare Therapeutics Inc. · Tests: FX-111 Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A) NCT06353386Phase 1, Phase 277 sites📍 La Jolla📍 Los Angeles📍 Miami Merck Sharp & Dohme LLC · Tests: Opevesostat, Olaparib, Docetaxel, Cabazitaxel, Fludrocortisone acetate Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) NCT06136624Phase 3288 sites📍 Orange📍 Palo Alto📍 Riverside Merck Sharp & Dohme LLC · Tests: Opevesostat, Abiraterone acetate, Enzalutamide, Hydrocortisone, Fludrocortisone acetate Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors NCT07288359Phase 1, Phase 216 sites📍 Atlanta📍 Nashville📍 San Antonio Novartis Pharmaceuticals · Tests: GVV858, Fulvestrant, Letrozole Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer NCT07002320Phase 1, Phase 24 sites📍 Bellinzona📍 Belfast📍 Cambridge Institute of Cancer Research, United Kingdom · Tests: SX-682, Apalutamide High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers NCT05011383Phase 217 sites📍 Aurora📍 West Haven📍 Gainesville VA Office of Research and Development · Tests: High dose testosterone Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer NCT06228053Phase 26 sites📍 Los Angeles📍 San Francisco📍 Ann Arbor Syntrix Biosystems, Inc. · Tests: SX-682, Enzalutamide Docetaxel or Cabazitaxel With or Without Darolutamide in mCRPC NCT05762536Phase 21 site📍 Rotterdam Erasmus Medical Center · Tests: Darolutamide, Docetaxel or cabazitaxel RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Failure NCT06663007Phase 1, Phase 21 site📍 Tianjin Tianjin Medical University Second Hospital · Tests: RC48, Envafolimab A Phase 3 Study of [177Lu]Ludotadipep for Metastatic Castration-Resistant Prostate Cancer NCT07853209Phase 38 sites📍 Gyeonggi-do📍 Seoul📍 Seoul FutureChem · Tests: [177-Lu]Ludotadipep, Best supportive care/standard of care (BSC/SOC) alone Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer NCT06145633Phase 21 site📍 Seattle Fred Hutchinson Cancer Center · Tests: Biopsy Procedure, Biospecimen Collection, Bone Scan, Computed Tomography, Fludeoxyglucose F-18 Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer NCT07667400Phase 1, Phase 21 site📍 Bethesda National Cancer Institute (NCI) · Tests: SX-682, DTX A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer NCT05800665Phase 126 sites📍 Scottsdale📍 New Haven📍 Orlando Genentech, Inc. · Tests: RO7656594 Study of DCC-2812 in Participants With Advanced Genitourinary Cancers NCT06966024Phase 18 sites📍 Boston📍 Ann Arbor📍 St Louis Deciphera Pharmaceuticals, LLC · Tests: DCC-2812 Study of Allogeneic Anti-PSMA CAR-NK Cell for Metastatic Castration-Resistant Prostate Cancer NCT07156045EARLY Phase 11 site📍 Beijing Cancer Institute and Hospital, Chinese Academy of Medical S… · Tests: anti-PSMA CAR-NK Kuopio Lutetium-177 Study in Patients with PSMA-Positive Metastatic Prostate Cancer NCT06850545n/a1 site📍 Kuopio Kuopio University Hospital A Phase I Clinical Study of HLX3902 in Patients With mCRPC and Other Advanced Tumours NCT07533708Phase 15 sites📍 Nanchang📍 Naning📍 Nanjing Shanghai Henlius Biotech · Tests: HLX3902 A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer NCT07005154Phase 254 sites📍 Huntsville📍 San Diego📍 Tampa Astellas Pharma Global Development, Inc. · Tests: ASP5541, Prednisone, Prednisolone, abiraterone acetate, Adrenocorticotropic hormone Targeted Radionuclide Therapy in Metastatic Prostate Cancer Using a New PSMA Ligand Radiolabelled With Terbium-161 (161Tb-SibuDAB) - Dose Identification/Escalation Phase Ia/b Study NCT06343038Phase 11 site📍 Basel University Hospital, Basel, Switzerland · Tests: Injection, 161Tb-SibuDAB,1GBq, Injection, 177Lu-PSMA-I&T, 1GBq, Injection, 161Tb-SibuDAB, Dose Escalation
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy